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Abstract
Respiratory dyskinesia is an under-recognized side
effect of neuroleptic administration. There are only few
studies that have addressed the prevalence of respiratory
dyskinesia in patients with tardive dyskinesia. Our case
report highlights the need to regularly examine patients on
antipsychotics for any evidence of dyskinetic movements
including respiratory musculature. Since RD is under-
recognized and misdiagnosed, early detection can improve
long term prognosis as treatment options are few and
usually of only limited effect.
A 62-year-old Asian male, retired civil engineer, had
more than 20 years history of depressive illness, developed
antidepressant induced hypomania, and was given
risperidone upto 1 mg per day. He developed extrapyrmidal
side effects as tremors, rigidity and later dyskinetic
movements of lips with shortness of breathing, dyspnoea,
grunting or gasping. He was referred to the pulmonologist
who got the neccessary medical work up done, which was
normal. A diagnosis of respiratory dyskinesia was made.
Respiratory dyskinesia is an under-recognised and
distressing condition that clinicians need to be aware of
when treating patients with anti-psychotic medications. And
also there is a need to regularly examine patients on
antipsychotics for any evidence of dyskinetic movements
including respiratory musculature for early diagnosis and
better outcome. This case report also is worth reading for
professionals of other specialties also because of the
presentation of this patient, it can be easily misdiagnosed
and result in poor outcome.
Keywords: Respiratory dyskinesias, Antipsychotic agents,
Adverse effects.
Introduction
Respiratory dyskinesia (RD) is an under-recognized
side effect of neuroleptic administration. It manifests as
irregular respiration, dyspnoea, grunting or gasping, and
abnormal chest or oesophageal movements. RD occurs
almost exclusively in association with other tardive effects
of neuroleptics, such as tardive dyskinesia (TD) and tardive
akathesia.1 When reviewing tardive dyskinesia, textbooks
and articles either fail to discuss this respiratory variant or
dismiss it as rare. It may mimic other respiratory or cardiac
disorders and is often overlooked or misdiagnosed.2-4
Case Report 
Mr. G .W, a 62 years old male, retired civil engineer,
had a +20 years history of depressive illness. He was being
treated with Mianserin for last 19 years, primarily to treat
his insomnia. He remained symptom free till January 2008,
when, as a result of non-availability of Mianserin he
experienced a relapse of his depressive symptoms as well as
insomnia. His treating psychiatrist started him on
Risperidone 1mg/day for insomnia, which he took for 2-3
weeks without any improvement. Consequently he
experienced involuntary movements of the neck along with
tremors in hands. Risperidone was therefore replaced with
Quetiapine 100mg/day. In addition he was started on
Sertraline 50mg/day for symptoms of depression such as
sadness, decreased interest in daily activities, sleep
disturbance and irritability. However as no improvement
was seen, Propranolol 30mg per day was added. He took
these medications till April 2008, when he discontinued the
Quetiapine by himself but continued Sertraline. The tremors
disappeared within 2 weeks. 
In June 2008 he presented at the psychiatry outpatient
clinic at Aga Khan University Hospital (AKUH) with
recurrence of his depressive symptoms. Following evaluation,
his Sertraline was increased up to 100mg/day. This led to
improvement in his depressive symptoms but he also started
showing symptoms of hypomania with elated mood, over-
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spending, grandiosity and psychomotor over-activity. Hence
Risperidone 1mg/day was re-introduced and Sertraline was
decreased. He responded well to this regime within a week
and, subsequently Risperidone was gradually reduced.
On reaching the dose of 0.5mg of Risperidone he
started experiencing shortness of breath. There was no
complaint of orthopnoea, paroxysmal nocturnal dyspnoea,
cyanosis, or peripheral edema. He demonstrated stereotypic
movements of lips and loud grunts and gasps with
inspiration and expiration were observed. Significantly, his
symptoms disappeared completely during sleep. The patient
did not smoke, and there was no history of tuberculosis or
chronic obstructive lung disease.
He was evaluated for his respiratory complaints by
both a pulmonologist and an ENT specialist. On
examination his respirations were very irregular with a rate
of 28 per minute. Investigations including sodium,
potassium, glucose, blood urea nitrogen, Creatinine, liver
functions test, complete blood count, electrocardiograph,
serum IgE, thyroid function tests, CT scan neck and chest,
were all normal. Pulmonary function tests were attempted
but could not be carried out as he could not apply his lips
effectively to the apparatus due to dyskinetic movements of
lips and irregular breathing. However, a six minutes
walking test was carried out which was normal and there
was no drop in O2 saturation.
A provisional diagnosis of "reactive airway disease"
was made and was given a trial of steroids, Montelukast, and
bronchodilators. However, as no improvement was observed
on follow-up visits, it was concluded that his dyspnoea and
breathing difficulties was most likely due to "psychogenic
causes" and he was referred for a psychiatric evaluation.
On assessment of his mental state our initial
impression was that the dyspnoea and difficulty in breathing
was due to anxiety, so he was started on Clonazepam
1mg/day, along with Sertraline 100mg/day. On follow-up
visits there was no improvement in his condition and a
provisional diagnosis of Respiratory Dyskinesia (RD) was
made. In view of the fact that some patients with RD
respond to small dose of antipsychotics,4 Risperidone
1mg/day was re-introduced. This resulted in almost
immediate relief in his symptoms. However, as the
respiratory symptoms re-emerged within next few weeks
Risperidone was reduced and discontinued, as it is advisable
in cases of TD to withdraw the antipsychotics if symptoms
re-emerge or worsen.4
He was re-referred for a pulmonology opinion which
again came out to be normal. A neurology opinion was also
sought, which confirmed the diagnosis of respiratory
dyskinesia and was advised Tetrabenazine 75mg/day along
with Clonazepam 2 mg (titrated upto 4 mg) per day in
divided doses. This resulted in significant improvement in
symptoms which also reduced the distress associated with
breathing problem to some extent. 
At the time of his last out-patient visit, August 2009,
the patient had maintained his improvement with an almost
80% reduction in his symptoms. At that time he was on the
treatment regime of Clonazepam 2mg per day, Sertraline
100mg per day and Trazadone 100mg day.
Discussion
The most common form of tardive dyskinesia (TD)
involves dyskinetic movements of the orofacial and
buccolingual musculature, manifesting as grimacing, facial
tics, lips smacking, chewing and wormlike movements of
the tongue. Involvement of the neck, axial, and extremity
musculature may also occur in the form of choreo-athetiod
movements, which on rare occasions may involve laryngo-
pharyngeal and respiratory muscles.5 RD generally starts
months or years after treatment with an antipsychotic.6
While the incidence of RD is not known, TD has an
estimated yearly incidence of 5% among adults and as high
as 25% in the elderly who receive continuous conventional
antipsychotic therapy.4 The risk of developing TD is
reported to increase with age and tends to be higher in
certain ethnic groups; female gender, substance use,
presence of mood disorders and early onset of EPS have
also been associated with increased risk of TD.5 There are
no clearly defined risk factors for RD, although older age
and organic brain syndrome are associated with the
condition.9
The cause of TD is uncertain, however it is thought
to be secondary to up-regulation of postsynaptic dopamine
receptors in the basal ganglia secondary to long term
dopamine blockade. This explanation is consistent with the
observation that TD may be aggravated by stopping of
antipsychotic drugs or by the administration of anti-
cholinergic anti-parkinsonian drugs.7
Our case report highlights the need to regularly
examine patients on antipsychotics for any evidence of
dyskinetic movements including respiratory musculature.
Since RD is under-recognized and misdiagnosed, early
detection can improve long term prognosis as treatment
options are few and usually of only limited effect.
There are only few studies that have addressed the
prevalence of RD in patients with tardive dyskinesia. When
data from these different studies are put together, the
prevalence of RD among patients with TD is on average
about 16 percent though prevalence figures in individual
studies range from 3-45 percent.2
The clinical presentation of our patient was very
similar to the cases of RD reported in the literature,8-10
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particularly the irregular pattern of breathing, tachypnoea,
grunting, with worsening of the symptoms with anxiety and
complete remission during sleep. Also, our patient
responded to tetrabenazine and benzodiazepines as reported
in other case reports.
In summary, respiratory dyskinesia is an under-
recognised and distressing condition that clinicians need to
be aware of when treating patients with anti-psychotic
medications. There is also need for further studies to
establish reliable diagnostic criterion and to establish more
effective treatment options for this distressing condition.
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